Biotechs request money for COVID therapeutics
German biotech companies and their industry association BIO Deutschland have called for appropriate investments into clinical COVID-19 therapies.
Polyneuron Pharmaceuticals AG extends Series A financing
Swiss auto-immunity specialist Polyneuron Pharmaceuticals AG has received CHF14m from HBM Healthcare Investments.
Mabion to licence COVID-19 jab from Vaxine Pty Ltd
Polish Mabion SA and Australian Vaxine Pty Ltd to develop Covax-19
MiNA Therapeutic bags £23m financing
RNA therapeutics specialist MiNA Therapeutics plc has secured £23m in a Series A financing to push development its first-in-class small activating RNA (saRNA) candidates.
Vaccine developers unite to stand with science
Nine CEOs of COVID-19 vaccines have assured that safety of vaccinated individuals remains their top priority in development of the first COVID-19 vaccines.
Scope Fluidics gets EIB loan for infection diagnostics
The European Investment Bank has lend up to 10m to Polish microbial diagnostics specialist Scope Fluidics AS.
COVID-19: Roche AG launches antigen rapid test
Roche has announced to launch a SARS-CoV-2 point-of-care antigen test this month co-developed with SD Biosensor Inc. (South Korea).
Unilever to replace fossil carbon in cleaning products
Unilever has announced to invest 1bn globally to eliminate fossil fuels as a source of carbon in its cleaning products by 2030.
Bioversys bags 17.7m financing
Swiss BioVersys AG has secured a CHF19m Series B financing to push clinincal development of two antiinfectives against drug-resistant pathogens.
Sotio licences Unum Therapeutics CAR-T cell portfolio
PPF-owned company SOTIO has acquired the rights to use the BOXR CAR-T platform and products from Cambridge-based Unum Therapeutics.